Stockreport

Tango Therapeutics Announces Discontinuation of TNG348 Program

Tango Therapeutics, Inc.  (TNGX) 
PDF – The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts –– Cash runway extended into 2027, [Read more]